List of Excipients in Branded Drug LOTREL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	CALCIUM PHOSPHATE
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	GELATIN
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	HYDROGENATED CASTOR OIL
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	HYPROMELLOSE
Novartis Pharmaceuticals Corporation	LOTREL	amlodipine besylate and benazepril hydrochloride	0078-0405	LACTOSE

# LOTREL Excipient Strategy and Commercial Opportunities in Amlodipine-Benazepril Fixed-Dose Capsules

Last updated: September 1, 2026

Lotrel is a fixed-dose combination of amlodipine besylate, a dihydropyridine calcium-channel blocker, and benazepril hydrochloride, an angiotensin-converting enzyme inhibitor. Its principal commercial opportunity is no longer basic molecule exclusivity. It is formulation execution: lower-cost generic supply, lactose-free or colorant-free capsules, improved moisture control, flexible dose presentation, and differentiated fixed-dose products.

The product has four approved strengths: 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg, and 10 mg/20 mg of amlodipine/benazepril, respectively. FDA-approved generic versions have materially reduced the value of the branded product, but the combination remains suitable for lifecycle products targeting adherence, tolerability, manufacturing efficiency, and patient-specific dosing.[1][2]

What is Lotrel and which excipients does it contain?

Lotrel contains amlodipine besylate and benazepril hydrochloride in a hard gelatin capsule. The marketed dosage form uses conventional oral solid-dose excipients rather than a modified-release delivery system.

Lotrel active ingredients and strengths

Lotrel strength	Amlodipine component	Benazepril component
Lotrel 2.5/10	2.5 mg amlodipine	10 mg benazepril
Lotrel 5/10	5 mg amlodipine	10 mg benazepril
Lotrel 5/20	5 mg amlodipine	20 mg benazepril
Lotrel 10/20	10 mg amlodipine	20 mg benazepril

The listed inactive ingredients include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, sodium starch glycolate, povidone, magnesium stearate, talc, colloidal silicon dioxide, titanium dioxide, and capsule colorants. The precise colorant profile varies by capsule strength.[1]

These excipients perform standard functions:

• Lactose monohydrate is a diluent.
• Microcrystalline cellulose is a filler and compression-supporting material.
• Pregelatinized starch contributes binding and disintegration.
• Crospovidone and sodium starch glycolate support capsule-content breakup.
• Povidone acts as a binder.
• Magnesium stearate reduces friction during manufacturing.
• Colloidal silicon dioxide improves powder flow.
• Talc and titanium dioxide support capsule appearance and opacity.
• Gelatin forms the capsule shell.

The excipient system is technically conventional. The commercial challenge is maintaining dissolution and bioequivalence while changing the composition, supplier, capsule shell, or manufacturing process.

What excipient strategy is most suitable for Lotrel generics?

The strongest strategy is a controlled formulation platform that preserves the release profile of both actives while reducing excipient-related regulatory and supply-chain risk.

Preserve dissolution across two active ingredients

Amlodipine and benazepril have different physical and biopharmaceutical characteristics. Amlodipine is administered at a low dose relative to the capsule fill, while benazepril hydrochloride contributes a larger mass. The formulation must achieve content uniformity for amlodipine without creating excessive segregation risk.

A practical development approach is:

1. Use a segregated or ordered-blend process for the low-dose amlodipine component.
2. Use a higher-mass benazepril excipient blend to control fill-weight variability.
3. Select a superdisintegrant system that delivers rapid capsule-content dispersion.
4. Control lubricant concentration and blending time because excessive magnesium stearate can impair wetting and dissolution.
5. Use low-moisture excipients and packaging to limit degradation during storage.

A dual-premix approach can improve content uniformity, but it adds process steps and validation burden. A one-pot blend may reduce manufacturing cost but requires strong flow and segregation controls.

Reduce lactose exposure

Lactose is a commercially important excipient risk because some patients avoid lactose, and some pharmaceutical buyers prefer lactose-free products. A lactose-free formulation could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a combination of these materials.

Each substitute creates tradeoffs:

Excipient option	Commercial advantage	Technical risk
Microcrystalline cellulose	Familiar, broadly available, strong compendial support	Higher bulk density and variable powder flow
Mannitol	Good patient perception and mouthfeel	Cost, hygroscopicity considerations, different dissolution behavior
Dibasic calcium phosphate	Low moisture uptake and strong flow	Potential incompatibility or pH effects
Spray-dried mannitol/cellulose blends	Improved flow and processability	Higher material cost and supplier dependence
Starch-based filler	Established use and low cost	Moisture and batch variability

A lactose-free product would have the greatest commercial value if it also avoids gelatin, artificial colorants, and animal-derived processing materials. The product would then appeal to institutional buyers and selected patient segments, although the clinical price premium may be limited in a mature generic market.

Avoid colorant and gelatin constraints

Lotrel uses hard gelatin capsules and colorants. A differentiated product could use:

• Hypromellose capsules.
• Pullulan capsules.
• Titanium-dioxide-free shells where technically and legally feasible.
• Iron-oxide or mineral-based color systems.
• Uncolored or imprint-only capsules.

The value proposition is strongest in markets with demand for vegetarian, halal, kosher, or clean-label dosage forms. Capsule-shell substitution requires evaluation of moisture transmission, mechanical strength, dissolution, stability, and compatibility with the fill blend. A shell change can be more consequential than an excipient change inside the capsule.

What formulations are protected by Lotrel patents?

The core combination is exposed to generic competition. FDA’s Orange Book lists approved drug products and relevant patent and exclusivity information, while approved ANDA products may use different inactive ingredients if they satisfy applicable bioequivalence and quality requirements.[2]

Lotrel’s historical protection centered on the combination of amlodipine and benazepril rather than a highly differentiated delivery technology. The commercial value of old formulation claims is therefore limited where:

• The relevant patent terms have expired.
• Generic manufacturers can use non-infringing excipient systems.
• The product is not dependent on a difficult manufacturing process.
• The brand has no current pediatric or new-indication exclusivity.

A formulation patent could still have value if it claims a narrow combination of particle size, blend architecture, capsule composition, moisture limits, or dissolution characteristics. Such claims would need to provide a meaningful technical distinction from prior Lotrel and generic formulations.

What patent opportunities remain for Lotrel formulations?

Potential new intellectual-property positions include:

• Lactose-free amlodipine-benazepril capsules.
• Hypromellose or pullulan capsule shells.
• Moisture-protective formulations with defined water activity.
• Stabilized benazepril formulations that reduce degradation products.
• Improved content uniformity for low-dose amlodipine.
• Multiparticulate or sprinkle formulations.
• Smaller capsule volumes for dysphagia-sensitive patients.
• Unit-dose packaging with defined oxygen and moisture barriers.
• Fixed-dose combinations with alternative dose ratios.
• Pediatric or geriatric dosage forms, if supported by clinical development.

The strongest patent claims would combine a measurable formulation property with a clinically or manufacturing-relevant result. Broad claims that merely substitute one ordinary filler for another would face substantial obviousness risk.

When does Lotrel lose exclusivity and what is the current Orange Book position?

Lotrel’s commercial exclusivity has already been overtaken by generic amlodipine-benazepril products. The original brand patents and regulatory exclusivities are historical rather than a barrier to current ANDA entry. FDA labeling and Orange Book records should be checked for the current reference-listed drug, patent listings, marketing status, and any changes to the listed product.[1][2]

The relevant entry pathways are:

• ANDA approval for a product therapeutically equivalent to the reference product.
• Paragraph IV certification if an applicant disputes an unexpired listed patent.
• Paragraph III certification where the applicant accepts a later patent date.
• 505(b)(2) development for a product with a meaningful formulation, dosage, or route difference.

For a conventional generic capsule, ANDA development is the likely route. A 505(b)(2) application becomes more relevant if the sponsor introduces a new capsule shell, sprinkle presentation, modified administration method, new dose ratio, or other feature that cannot be addressed through ordinary ANDA criteria.

Which companies are challenging Lotrel through generic products?

Generic competition has come from major ANDA manufacturers and specialty generic companies. The competitive set can include manufacturers such as Teva, Mylan/Viatris, Dr. Reddy’s Laboratories, Lupin, Zydus, Sandoz, and other FDA-approved suppliers, depending on current market authorization and availability.

The relevant competitive variables are:

Variable	Impact on Lotrel opportunity
Number of approved suppliers	More suppliers increase price pressure
Active supplier count	Shortages can create temporary pricing opportunities
Strength coverage	Incomplete strength portfolios create targeted entry gaps
Manufacturing location	Affects procurement and supply resilience
Capsule-shell source	Can create a differentiating or bottleneck input
Packaging format	Supports institutional and specialty-channel sales
FDA inspection history	Influences buyer confidence and continuity
Drug shortage status	Can create short-term commercial leverage

An entrant does not need to compete across all four strengths. A focused launch in the 2.5/10 mg or 10/20 mg strength could target gaps in supplier coverage, although a partial portfolio may be less attractive to large wholesalers.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue Lotrel-related opportunities through formulation support rather than direct product ownership.

Low-moisture and stability-enhancing excipients

Benazepril is susceptible to degradation under unfavorable environmental conditions. A supplier could position low-moisture microcrystalline cellulose, directly compressible mannitol, or engineered starch systems as tools for improving stability and reducing batch variability. The evidence must be based on comparative stability data rather than general excipient marketing.

Co-processed excipients

Co-processed filler-disintegrant systems may simplify manufacturing by combining flow, binding, and disintegration functions. This can reduce the number of raw materials and shorten blending operations.

The commercial value is highest where the excipient:

• Improves amlodipine content uniformity.
• Reduces capsule-fill weight.
• Supports high-speed encapsulation.
• Maintains dissolution after lubricant addition.
• Reduces sensitivity to supplier-to-supplier variation.

Capsule-shell platforms

Vegetarian capsule shells provide a direct product-differentiation route. The supplier must demonstrate equivalent or superior:

• Moisture transmission.
• Mechanical strength.
• Disintegration.
• Stability.
• Printing performance.
• Compatibility with the active blend.

A capsule supplier that can support regulatory documentation across multiple jurisdictions has an advantage over a commodity gelatin supplier.

Functional packaging

Excipient strategy should be paired with packaging. High-barrier blister packs, desiccant bottles, and unit-dose institutional packaging can reduce stability risk and support a premium positioning. Packaging patents may provide stronger practical protection than a broad excipient substitution claim.

How does Lotrel compare with other fixed-dose antihypertensive combinations?

Lotrel competes with generic fixed-dose combinations containing an ACE inhibitor or angiotensin-receptor blocker plus a calcium-channel blocker or diuretic.

Product class	Main commercial strength	Excipient and formulation opportunity
Amlodipine-benazepril	Established two-drug combination with multiple dose ratios	Lactose-free, shell substitution, improved stability
Amlodipine-valsartan	Broad use in hypertension and heart failure-related treatment strategies	Solubility and high-dose loading challenges
Amlodipine-lisinopril	Familiar ACE inhibitor/calcium-channel blocker pairing	Differentiation depends on dose flexibility and supply
Amlodipine-hydrochlorothiazide	Diuretic combination with low manufacturing complexity	Adherence and metabolic-tolerability positioning
ARB/calcium-channel blocker products	Strong generic and branded competition	Formulation value often depends on high-dose API handling

Lotrel’s advantage is the established combination and availability of multiple dose strengths. Its weakness is commoditization and limited room for premium pricing without a clear patient, payer, or supply-chain benefit.

What generic launch risks exist for Lotrel?

The principal risks are regulatory equivalence, formulation stability, and weak commercial differentiation.

Regulatory and technical risks

A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Excipients may differ, but the final product must meet quality, performance, labeling, and safety requirements. Key failure points include:

• Amlodipine content uniformity.
• Benazepril degradation during stability testing.
• Dissolution differences caused by lubricant or disintegrant selection.
• Capsule-shell moisture transfer.
• Inconsistent fill weight at commercial scale.
• Impurity-profile differences.
• Inadequate justification for excipient changes.

Commercial risks

The product is vulnerable to rapid price erosion once several suppliers are active. A differentiated excipient strategy will not protect margins if wholesalers treat the product as interchangeable. A sponsor should therefore link the formulation to a measurable commercial benefit, such as:

• Reduced shortage exposure.
• A hospital formulary requirement.
• A lactose-free procurement specification.
• A vegetarian capsule requirement.
• Improved shelf life in high-humidity markets.
• A smaller capsule for adherence or swallowing.

What licensing deals and partnerships are most relevant?

Lotrel itself is a legacy combination, so licensing value is more likely to arise from platform technology than from the branded product.

Potential deal structures include:

1. An excipient supplier licenses a co-processed filler-disintegrant platform to a generic manufacturer.
2. A capsule-shell supplier provides exclusive regional access to a hypromellose or pullulan shell.
3. A contract development and manufacturing organization develops a lactose-free formulation under a technology-transfer agreement.
4. A packaging company supplies a high-barrier bottle or blister system linked to a stability claim.
5. A specialty pharmaceutical company acquires regional rights to a differentiated fixed-dose combination.

The most defensible license package would include formulation know-how, analytical methods, stability data, supplier qualification, and regulatory support. A single excipient patent without manufacturing data would have limited negotiating leverage.

What is the litigation and Paragraph IV risk for Lotrel?

Current litigation risk is expected to be lower than during the original patent term because conventional generic products are already established. Paragraph IV risk matters primarily if a new patent is listed against a current reference product or if a sponsor develops a reformulated product with new patent claims.

A new formulation patent could trigger:

• Paragraph IV certification.
• A 30-month stay if statutory conditions are met.
• District-court patent litigation.
• At-risk launch exposure.
• Hatch-Waxman settlement negotiations.
• Launch-date restrictions tied to a settlement agreement.

The litigation strength of an excipient patent depends on claim specificity, written-description support, reproducibility, and evidence that the formulation produces an unexpected technical result. Claims directed only to routine excipient substitutions are less likely to withstand an obviousness challenge.

What FDA regulatory status applies to Lotrel and its excipient variants?

Lotrel is an FDA-approved prescription combination product. Conventional generic versions generally use the ANDA pathway, provided they match the reference product in dosage form, strength, route, conditions of use, and therapeutic performance.[1][3]

An excipient change can remain within an ANDA if it is supported by applicable FDA requirements and does not create an unaddressed difference from the reference product. A 505(b)(2) pathway may be more appropriate for:

• A new dosage form.
• A new route of administration.
• A sprinkle or opened-capsule presentation.
• A new dose ratio.
• A clinically differentiated formulation.
• A new patient population or indication.

FDA’s Inactive Ingredient Database can help assess prior use of candidate excipients in the relevant dosage form and route, but prior use does not remove the need for product-specific quality and equivalence data.[4]

How strong is the patent estate for an excipient-based Lotrel product?

The patent estate for a conventional Lotrel generic is weak if it relies only on ordinary excipient selection. A stronger estate would combine:

• Composition claims.
• Capsule-shell claims.
• Moisture or oxygen-control claims.
• Manufacturing-process claims.
• Dissolution or impurity-profile limitations.
• Packaging claims.
• Method-of-use claims for a differentiated administration format.

The best commercial position is usually a layered portfolio. One patent should not carry the entire product strategy. Trade secrets covering blend order, moisture conditioning, in-process controls, and supplier specifications can provide practical protection even when patent claims are narrow.

Key Takeaways

• Lotrel is an amlodipine-benazepril fixed-dose capsule available in four strengths.
• Its conventional excipient system includes lactose, microcrystalline cellulose, starches, povidone, crospovidone, sodium starch glycolate, magnesium stearate, talc, silicon dioxide, titanium dioxide, gelatin, and colorants.
• Core brand exclusivity has been overtaken by generic competition.
• The strongest formulation opportunities are lactose-free systems, vegetarian capsule shells, low-moisture formulations, improved content uniformity, and high-barrier packaging.
• Conventional excipient substitution alone is unlikely to support durable premium pricing or strong patent protection.
• Generic applicants face the greatest technical risk in content uniformity, benazepril stability, dissolution, and capsule-shell compatibility.
• The most credible commercial strategy combines formulation differentiation with supply resilience, regulatory support, and a targeted institutional or specialty-market position.
• No biosimilar pathway applies because Lotrel is a small-molecule combination product, not a biologic.

FAQs

Can Lotrel capsules be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. The reformulated product must demonstrate acceptable stability, content uniformity, dissolution, and bioequivalence or other applicable FDA requirements.

Is a vegetarian Lotrel capsule commercially viable?

Yes, but the opportunity depends on whether the product secures a procurement advantage or patient-facing differentiation. Hypromellose and pullulan shells are the most relevant alternatives to gelatin.

Can an excipient change support a new Lotrel patent?

It can, but routine substitution is unlikely to provide strong protection. A patent position is stronger when the formulation delivers an unexpected stability, dissolution, manufacturing, or patient-use benefit supported by comparative data.

Does Lotrel have biosimilar competition?

No. Lotrel contains small-molecule active ingredients. Competitive products are generics approved primarily through the ANDA pathway, not biosimilars approved under the Public Health Service Act.

What is the best commercial entry strategy for a new Lotrel manufacturer?

A focused entry should target an underserved strength or supply channel and combine a reliable API supply with a differentiated excipient or capsule platform. A full four-strength portfolio improves wholesaler relevance but increases development, inventory, and validation costs.

References

1. U.S. Food and Drug Administration. (n.d.). Lotrel prescribing information: Amlodipine besylate and benazepril hydrochloride capsules. FDA/DailyMed labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format of an ANDA. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.